While the supplementation of exogenous estrogen and phytoestrogens has been implicated in reducing the severity of menopause symptoms, the overaction of ER-α leads to an increased risk of cancer, whereas the activation of ER-β suppresses the proliferation of these tumor cells[22–23]. The gene discussed is ESR2; the disease is cancer.